Alvotech (ALVO) Reports Q3 Loss, Misses Revenue Estimates

Alvotech (ALVO) reported a Q3 loss of $0.02 per share, significantly missing the Zacks Consensus Estimate of a $0.05 profit, and revenues of $113.86 million, which fell 11.6% below expectations. This weak performance, a stark contrast to last year's earnings, has contributed to the stock's 57.8% year-to-date decline, severely underperforming the S&P 500. Consequently, Alvotech currently holds a Zacks Rank #4 (Sell) due to unfavorable earnings estimate revisions, indicating potential continued market underperformance.

Analysis

Alvotech (ALVO) reported a Q3 loss of $0.02 per share, significantly missing the Zacks Consensus Estimate of a $0.05 profit and falling short of last year's $0.19 EPS. Quarterly revenues of $113.86 million also missed consensus by 11.6%, despite representing a year-over-year increase from $102.99 million. This marks a -140.00% earnings surprise for the quarter.

The company's stock has severely underperformed the broader market, losing 57.8% year-to-date compared to the S&P 500's 16.4% gain. While Alvotech has surpassed EPS estimates two times and revenue estimates three times over the last four quarters, the recent unfavorable earnings estimate revisions have led to a Zacks Rank #4 (Sell), indicating anticipated near-term market underperformance.

This bearish outlook for Alvotech contrasts with its industry, Medical - Biomedical and Genetics, which is positioned in the top 34% of Zacks industries. Future consensus estimates project a -$0.03 EPS on $159.54 million in revenues for the coming quarter and $0.07 EPS on $576.57 million for the full fiscal year. The sustainability of the stock's immediate price movement will largely depend on management's commentary during the upcoming earnings call.

Key Decisions for Investors

• Investors should exercise caution given Alvotech's significant Q3 earnings and revenue misses, which contributed to its substantial 57.8% year-to-date underperformance against the S&P 500.
• Monitor upcoming management commentary for future guidance, as current unfavorable estimate revisions and a Zacks Rank #4 (Sell) suggest potential near-term underperformance.
• Assess whether the company's fundamentals can capitalize on the strong Medical - Biomedical and Genetics industry outlook, despite its current operational challenges.